jama naion semaglutide linked to increased risk of severe eye condition in new study Glucagon-like Peptide-1 Receptor Agonists and

Patients should contact their GP or prescribing clinician if they experience: Persistent leg pain lasting more than two weeks despite self-management measures Progressive worsening of symptoms over time Pain that significantly interferes with daily activities or sleep Bilateral leg swelling (affecting both legs) or unexplained weight gain suggesting fluid retention Muscle weakness that affects mobility or function Any concerns about symptom severity or progression Patients should seek same-day medical assessment (contact GP, NHS 111, or attend an urgent care centre) if they develop: Unilateral leg swelling, pain, warmth, and redness (possible DVT) Severe muscle pain with dark urine Leg pain accompanied by fever or signs of infection New neurological symptoms such as numbness or significant weakness Symptoms that cause considerable distress or anxiety Emergency care (999 or A&E) is required for: Chest pain, shortness of breath, or haemoptysis (coughing blood) alongside leg symptoms Sudden severe leg pain with absent pulses or cold, pale limb (possible arterial occlusion) Symptoms suggesting compartment syndrome (severe pain, tightness, neurovascular compromise) Healthcare professionals may need to review Wegovy dosing in line with the SmPC and NICE Technology Appraisal 875

Mannucci, M

Gradual Dose Titration Most semaglutide protocols start at 0.25 mg weekly and increase every 4 weeks

Your healthcare provider can help determine whether storage, genetics, or treatment timing explains any change in efficacy

Genetic variants associated with stronger GLP-1 receptor activity, for example, may correlate with more pronounced initial metabolic shiftspotentially affecting hydration status and hemoglobin levels relevant to plasma donation screening

Results may indicate a better fit with tirzepatide or GLP-Squared Injection, which activate different peptide pathways